Unicharm (OTCMKTS:UNICY – Get Free Report) and Dermata Therapeutics (NASDAQ:DRMA – Get Free Report) are both consumer staples companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, profitability, risk, earnings, analyst recommendations, institutional ownership and valuation.
Analyst Ratings
This is a breakdown of current ratings and recommmendations for Unicharm and Dermata Therapeutics, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Unicharm | 0 | 1 | 0 | 1 | 3.00 |
| Dermata Therapeutics | 1 | 0 | 1 | 0 | 2.00 |
Dermata Therapeutics has a consensus target price of $10.00, indicating a potential upside of 584.93%. Given Dermata Therapeutics’ higher possible upside, analysts plainly believe Dermata Therapeutics is more favorable than Unicharm.
Risk & Volatility
Insider & Institutional Ownership
8.7% of Dermata Therapeutics shares are owned by institutional investors. 21.9% of Dermata Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Earnings and Valuation
This table compares Unicharm and Dermata Therapeutics”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Unicharm | $6.32 billion | 1.64 | $436.93 million | $0.13 | 22.92 |
| Dermata Therapeutics | N/A | N/A | -$7.56 million | ($4.39) | -0.33 |
Unicharm has higher revenue and earnings than Dermata Therapeutics. Dermata Therapeutics is trading at a lower price-to-earnings ratio than Unicharm, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Unicharm and Dermata Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Unicharm | 6.65% | 7.15% | 5.25% |
| Dermata Therapeutics | N/A | -166.66% | -130.13% |
Summary
Unicharm beats Dermata Therapeutics on 9 of the 14 factors compared between the two stocks.
About Unicharm
Unicharm Corporation engages in the manufacturing and sale of wellness, feminine, baby and children, kirei, and pet care products in Japan and internationally. The company's baby and child care products, including disposable diapers and wipes under the Moony, MamyPoko, Oyasumiman, and Torepanman brands; feminine care products comprise napkins, tampons, panty liners, sanitary short, panty liners, and other feminine care products under the Sofy, Center-In, and Unicharm brand names; and wellness care products include napkin-type incontinence pads, pants-type diapers, tape-type diapers, pants-type specialized urine pads, and tape-type specialized urine pads under the Lifree and Charmnap brand. It also provides masks under the Unicharm brand; home care products, including cleaning sheets under the Wave brand name; cosmetic cotton and wet wipes under the Silcot brand; and paper towels under the Cook Up brand name. In addition, the company offers pet care products that include pet foods, excrement cleanup sheets, system toilets, and disposable diapers under the Grand Deli, Best Balance, Physicalife Dog, Silver Plate, Aiken Genki, Manner Wear, Deo Sheet, Silver Spoon, AllWell, Physicalife Cat, Deo Toilet, Deo Sand, Deo Clean, and Neko Genki brands; and deodorizing beads. Further, it is involved in the manufacture and sale of industrial materials related products, etc., as well as food-packaging materials. Unicharm Corporation was incorporated in 1941 and is headquartered in Tokyo, Japan.
About Dermata Therapeutics
Dermata Therapeutics, Inc., a late-stage medical dermatology company, focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions and diseases. The company's lead product candidate is DMT310, which has completed Phase IIb clinical trial for treatment of moderate-to-severe acne; and Phase Ib proof of concept (POC) trial for Mild-to-Moderate Psoriasis, as well as is in a Phase 2 clinical trial for treatment of moderate-to-severe rosacea. It is also developing DMT410 that has completed Phase Ib POC trials for the treatment of anxillary hyperhidrosis and aesthetic conditions. Dermata Therapeutics, Inc. was incorporated in 2014 and is headquartered in San Diego, California.
Receive News & Ratings for Unicharm Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Unicharm and related companies with MarketBeat.com's FREE daily email newsletter.
